Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

Empagliflozin reduces podocyte lipotoxicity in experimental Alport syndrome

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are anti-hyperglycemic agents that prevent glucose reabsorption in proximal tubular cells. SGLT2i improves renal outcomes in both diabetic and non-diabetic patients, indicating it may have beneficial effects beyond glycemic control. Here, we demonst...

Full description

Bibliographic Details
Main Authors: Mengyuan Ge, Judith Molina, Jin-Ju Kim, Shamroop K Mallela, Anis Ahmad, Javier Varona Santos, Hassan Al-Ali, Alla Mitrofanova, Kumar Sharma, Flavia Fontanesi, Sandra Merscher, Alessia Fornoni
Format: Article
Language:English
Published: eLife Sciences Publications Ltd 2023-05-01
Series:eLife
Subjects:
Alport syndrome
lipid
energy substrate
SGLT2 inhibitor
Online Access:https://elifesciences.org/articles/83353

Internet

https://elifesciences.org/articles/83353

Similar Items